Abortion providers plan patient options after mifepristone access restrictions
Updated
Updated · NBC News · May 5
Abortion providers plan patient options after mifepristone access restrictions
9 articles · Updated · NBC News · May 5
The 5th Circuit Court of Appeals over the weekend restored an in-person dispensing rule for the abortion pill, blocking telehealth prescribing and mail delivery.
Providers were left scrambling to determine how patients could still obtain medication abortions under the revived requirement and what alternative care pathways remain available.
The ruling abruptly narrows access to mifepristone and forces clinics to adjust operations as patients face new travel, timing and logistical barriers.
What happens to nationwide medication access if the Supreme Court's temporary hold expires?
Can a state's financial claims overrule the FDA's scientific authority on drug safety?
Could a 150-year-old law be used to halt the mailing of modern medicines?
Supreme Court's May 2026 Stay Preserves Telehealth Access to Mifepristone Amid Legal Battle
Overview
On May 4, 2026, Justice Samuel Alito issued a temporary stay that halted the Fifth Circuit's ruling requiring in-person pickup of mifepristone, restoring nationwide telehealth and mail access to the medication. This stay preserves the FDA's 2021 policy allowing remote prescriptions and mail delivery, maintaining critical abortion access for many, especially in restrictive states. The Fifth Circuit had ruled in favor of Louisiana, which argued that the FDA's policy violated state sovereignty by enabling residents to bypass abortion bans. The ruling blocked telehealth access, creating severe burdens for vulnerable communities and prompting emergency appeals by drug manufacturers. The Supreme Court must decide by May 11 whether to extend the stay or reinstate the restrictions, a decision with profound national implications for abortion access and federal regulatory authority.